Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Toinv

Rank: President [?]

Points: 4389 [?]

Votes: 35 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

posted on Jun 23, 2022 10:59AM

Good find jonzo.

Study completion in May 2024. Cancer trials move fast, do they Don?

Cheers

Impatient Toinv

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply